Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | USP1 | O94782 | 1/20 | 0.38 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159785 | 1.00 | CYP2D6 (0.41) | CYP2D6DRD2DRD4DRD3MMP9 | |
| SCHEMBL14116703 | 1.00 | CYP2D6 (0.41) | CYP2D6DRD2DRD4DRD3MMP9 | |
| SCHEMBL6751629 | 1.00 | CYP2D6 (0.41) | CYP2D6DRD2DRD4DRD3MMP9 | |
| SCHEMBL1338239 | 0.85 | MAOB (0.41) | MAOBALDH1A1 | |
| SCHEMBL19365539 | 0.85 | ALDH1A1 (0.40) | CYP2D6MMP9USP1WDR48MAOB | |
| SCHEMBL6428936 | 0.85 | ALDH1A1 (0.40) | CYP2D6MMP9USP1WDR48MAOB | |
| SCHEMBL6428933 | 0.85 | ALDH1A1 (0.40) | CYP2D6MMP9USP1WDR48MAOB | |
| SCHEMBL1338859 | 0.84 | TSHR (0.44) | CYP2D6DRD2DRD4DRD3KDM4E | |
| SCHEMBL11128460 | 0.84 | DRD2 (0.43) | DRD2DRD4DRD3MMP9USP1 | |
| SCHEMBL4354314 | 0.84 | DRD2 (0.43) | DRD2DRD4DRD3MMP9USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919887-B1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC (US) | 2015-02-18 | — | — | EP | disclosed |
| US-8716497-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-8263790-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2012-09-11 | — | — | US | disclosed |
| US-20120004427-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-7960573-B2 | Method for enantioselective hydrogenation of chromenes | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100069653-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | Children hospital medical center (US) | 2010-03-18 | — | — | US | disclosed |
| US-7528267-B2 | Method for enantioselective hydrogenation of chromenes | GIRINDUS AMERICA, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| EP-1919887-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | Girindus America, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007016423-A2 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | GIRINDUS AMERICA INC. (US) | 2007-02-08 | — | — | WO | disclosed |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | AUSIO PHARMACEUTICALS, LLC | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116450-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | CYP2D6 1651/4885DRD2 960/4885DRD4 534/4885 |
| US-20070027329-A1 | Method for enantioselective hydrogenation of chromenes | HRH3, HRH2, CHD8 | CYP2D6 1651/4885DRD2 960/4885DRD4 534/4885 |
| US-20120004427-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | CYP2D6 1651/4885DRD2 960/4885DRD4 534/4885 |
| US-20100069653-A1 | METHOD FOR ENANTIOSELECTIVE HYDROGENATION OF CHROMENES | HRH3, HRH2, CHD8 | CYP2D6 1651/4885DRD2 960/4885DRD4 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.